408 related articles for article (PubMed ID: 17555455)
21. The influence of poly-N-[(2,2-dimethyl-1,3-dioxolane)methyl]acrylamide on fibrin polymerization, cross-linking and clot structure.
Lai BF; Zou Y; Brooks DE; Kizhakkedathu JN
Biomaterials; 2010 Aug; 31(22):5749-58. PubMed ID: 20435346
[TBL] [Abstract][Full Text] [Related]
22. Surfactant incorporation markedly alters mechanical properties of a fibrin clot.
Günther A; Kalinowski M; Rosseau S; Seeger W
Am J Respir Cell Mol Biol; 1995 Dec; 13(6):712-8. PubMed ID: 7576709
[TBL] [Abstract][Full Text] [Related]
23. Molecular basis of fibrin clot elasticity.
Lim BB; Lee EH; Sotomayor M; Schulten K
Structure; 2008 Mar; 16(3):449-59. PubMed ID: 18294856
[TBL] [Abstract][Full Text] [Related]
24. The ultrastructure of fibrinogen-420 and the fibrin-420 clot.
Mosesson MW; DiOrio JP; Hernandez I; Hainfeld JF; Wall JS; Grieninger G
Biophys Chem; 2004 Dec; 112(2-3):209-14. PubMed ID: 15572250
[TBL] [Abstract][Full Text] [Related]
25. Substitution of tyrosine for phenylalanine in fibrinopeptide A results in preferential thrombin cleavage of fibrinopeptide B from fibrinogen.
Rooney MM; Mullin JL; Lord ST
Biochemistry; 1998 Sep; 37(39):13704-9. PubMed ID: 9753458
[TBL] [Abstract][Full Text] [Related]
26. Streptococcus gordonii FSS2 Challisin affects fibrin clot formation by digestion of the αC region and cleavage of the N -terminal region of the Bβ chains of fibrinogen.
Harty DW; Farahani RM; Simonian MR; Hunter L; Hunter N
Thromb Haemost; 2012 Aug; 108(2):236-46. PubMed ID: 22552295
[TBL] [Abstract][Full Text] [Related]
27. Fibrin clot structure in patients with end-stage renal disease.
Sjøland JA; Sidelmann JJ; Brabrand M; Pedersen RS; Pedersen JH; Esbensen K; Standeven KF; Ariëns RA; Gram J
Thromb Haemost; 2007 Aug; 98(2):339-45. PubMed ID: 17721616
[TBL] [Abstract][Full Text] [Related]
28. Altered structure and function of fibrinogen after cleavage by Factor VII Activating Protease (FSAP).
Etscheid M; Subramaniam S; Lochnit G; Zabczyk M; Undas A; Lang IM; Hanschmann KM; Kanse SM
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3397-3406. PubMed ID: 30076961
[TBL] [Abstract][Full Text] [Related]
29. [Clinical significance of fibrinogen/fibrin degradation products (F/F DP)].
Alakhverdian R
Vutr Boles; 1979; 18(3):160-7. PubMed ID: 89851
[No Abstract] [Full Text] [Related]
30. Effects of acetylsalicylic acid on increase of fibrin network porosity and the consequent upregulation of fibrinolysis.
He S; Bark N; Wang H; Svensson J; Blombäck M
J Cardiovasc Pharmacol; 2009 Jan; 53(1):24-9. PubMed ID: 19129740
[TBL] [Abstract][Full Text] [Related]
31. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
[TBL] [Abstract][Full Text] [Related]
32. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system.
Ajjan RA; Standeven KF; Khanbhai M; Phoenix F; Gersh KC; Weisel JW; Kearney MT; Ariëns RA; Grant PJ
Arterioscler Thromb Vasc Biol; 2009 May; 29(5):712-7. PubMed ID: 19286636
[TBL] [Abstract][Full Text] [Related]
33. Two cases of congenital dysfibrinogenemia associated with thrombosis - Fibrinogen Praha III and Fibrinogen Plzen.
Kotlín R; Reicheltová Z; Malý M; Suttnar J; Sobotková A; Salaj P; Hirmerová J; Riedel T; Dyr JE
Thromb Haemost; 2009 Sep; 102(3):479-86. PubMed ID: 19718467
[TBL] [Abstract][Full Text] [Related]
34. Degradation of cross-linked fibrin by human leukocyte proteases.
Francis CW; Marder VJ
J Lab Clin Med; 1986 Apr; 107(4):342-52. PubMed ID: 3514776
[TBL] [Abstract][Full Text] [Related]
35. Fibrinogens Bern IV, Bern V and Milano XI: three dysfunctional variants with amino acid substitutions in the thrombin cleavage site of the Aalpha-chain.
Stucki B; Zenhäusern R; Biedermann B; Baudo F; Redaelli R; Lämmle B; Furlan M
Blood Coagul Fibrinolysis; 1999 Mar; 10(2):93-9. PubMed ID: 10192658
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of activated factor XIII by polymorphonuclear granulocyte proteases within fibrin clot.
Bagoly Z; Haramura G; Muszbek L
Thromb Haemost; 2007 Aug; 98(2):359-67. PubMed ID: 17721618
[TBL] [Abstract][Full Text] [Related]
37. Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure.
Henderson SJ; Xia J; Wu H; Stafford AR; Leslie BA; Fredenburgh JC; Weitz DA; Weitz JI
Thromb Haemost; 2016 Mar; 115(3):533-42. PubMed ID: 26489782
[TBL] [Abstract][Full Text] [Related]
38. Influence of gamma' fibrinogen splice variant on fibrin physical properties and fibrinolysis rate.
Collet JP; Nagaswami C; Farrell DH; Montalescot G; Weisel JW
Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):382-6. PubMed ID: 14656741
[TBL] [Abstract][Full Text] [Related]
39. Structural examination of the influence of phosphorylation on the binding of fibrinopeptide A to bovine thrombin.
Maurer MC; Peng JL; An SS; Trosset JY; Henschen-Edman A; Scheraga HA
Biochemistry; 1998 Apr; 37(17):5888-902. PubMed ID: 9558322
[TBL] [Abstract][Full Text] [Related]
40. Biophysical characterization of fibrinogen Caracas I with an Aalpha-chain truncation at Aalpha-466 Ser: identification of the mutation and biophysical characterization of properties of clots from plasma and purified fibrinogen.
Marchi R; Meyer M; de Bosch N; Soria J; Arocha-Piñango CL; Weisel JW
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):285-93. PubMed ID: 15166913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
